T-Cypher Bio extends footprint in purpose-built laboratory space at Abingdon Science Park, Oxford

T-Cypher Bio ("T-Cypher), a biotechnology company developing novel T cell receptor (TCR)-based T cell engagers that target high copy number antigens, today announced its relocation to Abingdon Science Park, Oxford, UK.

The new facility at Barton House extends the Company's footprint to support development of its pipeline of novel immune engager therapeutics targeting areas of high unmet need in solid tumors and autoimmune disease. Developed by Kadans Science Partner ("Kadans"), a leading investor in the development of real estate and ecosystems with a dedicated focus on knowledge intensive sectors, the site has been purpose-built to provide specialist facilities to meet T-Cypher's operational requirements.

T-Cypher was founded as a deep tech company and has developed a fully integrated discovery platform and machine-learning engine, T-C Alpha (T-Ca^™), to profile the human disease target space and its associated T cell reactivity. The platform combines proprietary computational and wet-lab systems to identify high copy number targets and enable the development of next-generation therapeutics. Relocating its headquarters will support T-Cypher's future growth as these assets progress towards the clinic.

Abingdon Science Park is a 500,000 sq ft life science and innovation campus located within the world-renowned Oxford ecosystem. The campus is home to companies such as Penlon, Alethio Therapeutics, Sense Bio and Capgemini. The newly built Barton House provides T-Cypher with 12,000 sq.ft. of purpose-built space including Containment Level 2 wet laboratories and open plan office spaces. The facilities are ideally located within the wider Oxford ecosystem and leverage Kadans' strong European-wide life sciences network, creating opportunities for collaboration, knowledge-sharing and partnership development. On-site amenities, including Barton Café, and access to the surrounding Oxfordshire countryside further enhance the working environment.

Moving to Barton House allowed the expansion of our tissue culture space, critical to the in-vitro work needed for our IND-enabling studies, as we progress towards the clinic. Working with Kadans has allowed us to be involved in the design process from the start, ensuring the new space meets our requirements and enabling a seamless transition between sites with minimal disruption to our research activities."

Sarah Leonard, Chief Executive Officer, T-Cypher Bio

Sarah added: "We have been impressed throughout by both the quality and speed of the fit-out; the expertise and responsiveness of the Kadans team has been instrumental in creating a laboratory environment completely tailored to our scientific needs. Settling into our new home on Abingdon Science Park is an exciting milestone as we look ahead to the future of our company and its vision for building next gen-TCR-based bispecifics in oncology and autoimmune disease."

Katie Nelson, Head of Leasing UK&I, Kadans Science Partner, said: "T-Cypher required a facility that could accommodate specialist laboratory infrastructure while remaining within the dynamic Oxford science ecosystem. By involving the team throughout the design and delivery process, we were able to create a purpose-built space including specialist labs tailored exactly to the Company. This project demonstrates how Kadans works with scientific organizations through every step of the process - we are proud to welcome another transformative company to our community and be part of T-Cypher's growth in this way."